Howard Liang Sells 40,000 Shares of Beigene Ltd (BGNE) Stock
Beigene Ltd (NASDAQ:BGNE) CFO Howard Liang sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $160.27, for a total value of $6,410,800.00. Following the completion of the transaction, the chief financial officer now directly owns 15,872 shares in the company, valued at $2,543,805.44. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Howard Liang also recently made the following trade(s):
- On Friday, March 16th, Howard Liang sold 10,872 shares of Beigene stock. The stock was sold at an average price of $157.07, for a total value of $1,707,665.04.
Beigene stock opened at $177.22 on Thursday. The company has a quick ratio of 6.02, a current ratio of 6.09 and a debt-to-equity ratio of 0.23. Beigene Ltd has a 1 year low of $34.36 and a 1 year high of $182.79. The firm has a market cap of $8,763.77, a P/E ratio of -72.63 and a beta of 0.58.
A number of hedge funds have recently bought and sold shares of BGNE. Quantbot Technologies LP bought a new position in Beigene in the 3rd quarter worth approximately $160,000. Tower Research Capital LLC TRC bought a new position in Beigene in the 4th quarter worth approximately $182,000. Comerica Bank bought a new position in Beigene in the 4th quarter worth approximately $246,000. Teachers Retirement System of The State of Kentucky bought a new position in Beigene in the 3rd quarter worth approximately $248,000. Finally, Mackenzie Financial Corp bought a new position in Beigene in the 4th quarter worth approximately $250,000. Hedge funds and other institutional investors own 51.47% of the company’s stock.
Several research analysts have recently commented on the company. Maxim Group set a $120.00 target price on Beigene and gave the stock a “buy” rating in a report on Monday, January 22nd. Morgan Stanley reissued an “overweight” rating and issued a $200.00 target price (up from $93.00) on shares of Beigene in a report on Wednesday. Cowen reissued a “buy” rating on shares of Beigene in a report on Monday, January 8th. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $172.00 target price on shares of Beigene in a report on Thursday, March 1st. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded Beigene from a “hold” rating to a “sell” rating in a report on Monday, January 8th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Beigene presently has a consensus rating of “Buy” and a consensus target price of $145.17.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.